Anatomic Stage I Breast Cancer AJCC v8NCT05568472
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
A study testing Best Practice, Biospecimen Collection and Endocrine Drug Therapy in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, run by SWOG Cancer Research Network at 490 sites in 2 countries.
Trial summary
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- What is being tested?
- Best Practice, Biospecimen Collection and Endocrine Drug Therapy
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 565 participants
- Where
- 490 sitesin 2 countries
- Study dates
- 29 Mar 2023to 1 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must be female and have Stage I, II, or III hormone receptor positive breast cancer based on clinical or pathologic evaluation
- Participants must have been pre- or peri-menopausal at the time of breast cancer diagnosis by satisfying one of the following:
- had a menstrual period (by self-report) within the 12 months before breast cancer diagnosis, or
- had a serum or plasma estradiol and/or follicle stimulating hormone (FSH) concentration consistent with premenopausal status (based on institutional standards) within the 12 months before breast cancer diagnosis or when checked after breast cancer diagnosis
- Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole; within 14 days prior to randomization or be planning to start initial treatment with standard of care oral ET within 14 days after randomization
- Participants who currently have ovarian function (estradiol above the postmenopausal range) must be planning to undergo ovarian suppression or ablation concomitantly with oral ET medication, starting before or at the same time as oral ET initiation. Participants with chemotherapy-induced amenorrhea or ovarian failure at time of registration must be planning to start ovarian suppression or ablation if they have recurrence of ovarian function during study participation (circulating estradiol concentration in the premenopausal range or recurrence of menses)
Show all 17Show fewer
- Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization NOTE: Concomitant radiotherapy at the time of randomization and/or during study participation is allowed
- Participants who received chemotherapy must have finished it at least 14 days prior to randomization NOTE: Concomitant maintenance targeted or biologic therapy (e.g., human epidermal growth factor receptor 2 [anti-HER2] therapy, poly-ADP ribose polymerase [PARP] inhibitor therapy, CDK4/6 inhibitor therapy, osteoclast inhibitor therapy) at the time of randomization and/or during study participation is allowed
- Participants must be >= 18 years of age
- Participants must have a complete medical history within 60 days prior to randomization
- Participants must be able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish
- Participants must:
- agree to complete PROs at all scheduled assessments and
- complete the pre-registration (baseline) PRO forms within 14 days prior to randomization
- Participants must be able to complete symptom questions on a web browser (on a smartphone, tablet, or computer) or respond via voice on a telephone in English or Spanish. Participants must agree to complete symptom questions at all scheduled assessments NOTE: Participants who do not have access to the internet and who cannot receive telephone calls for interactive voice response system (IVRS) assessments are not eligible
- Participants must be offered the opportunity to participate in specimen banking for translational medicine. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) specimen tracking system
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Who cannot join
- Participants must not have distant metastatic breast cancer
- Participants who have started or plan to start treatment with tamoxifen during study participation must not have received prior tamoxifen for treatment or prevention of breast cancer
- Participants who have started or plan to start treatment with an aromatase inhibitor during study participation must not have received prior aromatase inhibitor therapy for treatment or prevention of breast cancer
- Participants must not be taking or planning to take oral estrogen-or progesterone-containing treatments during study participation
- NOTES:
- Participants who start or plan to start treatment with an aromatase inhibitor may have previously received tamoxifen for prevention of breast cancer or treatment of a prior cancer
Show all 10Show fewer
- Participants may have received prior treatment with an aromatase inhibitor for infertility treatment
- Participants must not be planning to become pregnant during the 80 weeks of study participation
- Participants must not receive additional anti-cancer treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial
- Participants must not have a non-breast malignancy for which they are currently receiving treatment
Trial locations and contacts
490 sites in 2 countries.
301 sites in 2 countries
United States300 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii, 96706
Summa Health System - Akron Campus
Akron, Ohio, 44304
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic - Ames
Ames, Iowa, 50010
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California, 93420
PCR Oncology
Arroyo Grande, California, 93420
Northside Hospital
Atlanta, Georgia, 30342
Rush - Copley Medical Center
Aurora, Illinois, 60504
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, 93301
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin, Missouri, 63011
Mercy Medical Center
Baltimore, Maryland, 21202
Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland, 21244
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Beverly Hospital
Beverly, Massachusetts, 01915
Billings Clinic Cancer Center
Billings, Montana, 59101
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
McFarland Clinic - Boone
Boone, Iowa, 50036
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison Medical Center
Bremerton, Washington, 98310
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Kaiser Permanente-Burke Medical Center
Burke, Virginia, 22015
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Cambridge Medical Center
Cambridge, Minnesota, 55008
Marshall Cancer Center
Cameron Park, California, 95682
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, 48188
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
AtlantiCare Health Park-Cape May Court House
Cape May Court House, New Jersey, 08210
Mercy Cancer Center �� Carmichael
Carmichael, California, 95608
Mercy San Juan Medical Center
Carmichael, California, 95608
Caro Cancer Center
Caro, Michigan, 48723
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Centralia Oncology Clinic
Centralia, Illinois, 62801
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, 48118
Northwestern University
Chicago, Illinois, 60611
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
Morton Plant Hospital
Clearwater, Florida, 33756
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Main Line Health Center-Collegeville
Collegeville, Pennsylvania, 19426
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
Saint Francis Cancer Center
Colorado Springs, Colorado, 80923
Mercy Hospital
Coon Rapids, Minnesota, 55433
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Greater Regional Medical Center
Creston, Iowa, 50801
AMG Crystal Lake - Oncology
Crystal Lake, Illinois, 60014
Aurora Saint Luke's South Shore
Cudahy, Wisconsin, 53110
Carle at The Riverfront
Danville, Illinois, 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Broward Health North
Deerfield Beach, Florida, 33064
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Porter Adventist Hospital
Denver, Colorado, 80210
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Mission Cancer and Blood - Laurel
Des Moines, Iowa, 50314
Ascension Saint John Hospital
Detroit, Michigan, 48236
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Bayhealth Hospital Kent Campus
Dover, Delaware, 19901
Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
Epic Care-Dublin
Dublin, California, 94568
Kaiser Permanente Dublin
Dublin, California, 94568
Northside Hospital - Duluth
Duluth, Georgia, 30096
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Great Lakes Cancer Management Specialists-Doctors Park
East China, Michigan, 48054
Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
STCC at DHR Health Institute for Research and Development
Edinburg, Texas, 78539
Swedish Cancer Institute-Edmonds
Edmonds, Washington, 98026
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
AtlantiCare Surgery Center
Egg Harbor, New Jersey, 08234
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Advocate Sherman Hospital
Elgin, Illinois, 60123
Mercy Cancer Center - Elk Grove
Elk Grove, California, 95758
Christiana Care - Union Hospital
Elkton, Maryland, 21921
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Main Line Health Center-Exton
Exton, Pennsylvania, 19341
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, 50501
Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Beebe South Coastal Health Campus
Frankford, Delaware, 19945
Kaiser Permanente-Fremont
Fremont, California, 94538
Fresno Cancer Center
Fresno, California, 93720
Kaiser Permanente-Fresno
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg, Maryland, 20879
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Grand Valley Oncology
Grand Junction, Colorado, 81505
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan, 48236
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, 48236
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, 17109
HaysMed University of Kansas Health System
Hays, Kansas, 67601
Advocate South Suburban Hospital
Hazel Crest, Illinois, 60429
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania, 18201
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
GenesisCare USA - Henderson
Henderson, Nevada, 89074
Las Vegas Urology - Green Valley
Henderson, Nevada, 89074
Las Vegas Urology - Pebble
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Hawaii Diagnostic Radiology Services LLC
Honolulu, Hawaii, 96817
Kuakini Medical Center
Honolulu, Hawaii, 96817
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Edwards Comprehensive Cancer Center
Huntington, West Virginia, 25701
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
University of Mississippi Medical Center
Jackson, Mississippi, 39216
McFarland Clinic - Jefferson
Jefferson, Iowa, 50129
Capital Region Southwest Campus
Jefferson City, Missouri, 65109
Jupiter Medical Center
Jupiter, Florida, 33458
Straub Medical Center - Kahului Clinic
Kahului, Hawaii, 96732
Castle Medical Center
Kailua, Hawaii, 96734
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Ascension Borgess Cancer Center
Kalamazoo, Michigan, 49009
Borgess Medical Center
Kalamazoo, Michigan, 49048
Kalispell Regional Medical Center
Kalispell, Montana, 59901
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Truman Medical Centers
Kansas City, Missouri, 64108
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Kaiser Permanente - Kensington Medical Center
Kensington, Maryland, 20895
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kingman Regional Medical Center
Kingman, Arizona, 86401
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin, 54848
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
The Watson Clinic
Lakeland, Florida, 33805
Saint Anthony Hospital
Lakewood, Colorado, 80228
Sparrow Hospital
Lansing, Michigan, 48912
Kaiser Permanente - Largo Medical Center
Largo, Maryland, 20774
Las Vegas Urology - Pecos
Las Vegas, Nevada, 89074
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
Urology Specialists of Nevada - Central
Las Vegas, Nevada, 89106
GenesisCare USA - Las Vegas
Las Vegas, Nevada, 89109
Sunrise Hospital and Medical Center
Las Vegas, Nevada, 89109
Las Vegas Prostate Cancer Center
Las Vegas, Nevada, 89113
Las Vegas Urology - Sunset
Las Vegas, Nevada, 89113
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Ann M Wierman MD LTD
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
GenesisCare USA - Vegas Tenaya
Las Vegas, Nevada, 89128
Las Vegas Urology - Cathedral Rock
Las Vegas, Nevada, 89128
Las Vegas Urology - Smoke Ranch
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
GenesisCare USA - Fort Apache
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
University Cancer Center
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Northside Hospital - Gwinnett
Lawrenceville, Georgia, 30046
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Beebe Medical Center
Lewes, Delaware, 19958
Saint Joseph Hospital
Lexington, Kentucky, 40504
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
AMG Libertyville - Oncology
Libertyville, Illinois, 60048
Condell Memorial Hospital
Libertyville, Illinois, 60048
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Littleton Adventist Hospital
Littleton, Colorado, 80122
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Saint Joseph London
London, Kentucky, 40741
Longmont United Hospital
Longmont, Colorado, 80501
Kaiser Permanente Lutherville - Timonium Medical Center
Lutherville, Maryland, 21093
Centra Lynchburg Hematology-Oncology Clinic Inc
Lynchburg, Virginia, 24501
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, 48044
Michigan Breast Specialists-Macomb Township
Macomb, Michigan, 48044
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan, 48453
McFarland Clinic - Marshalltown
Marshalltown, Iowa, 50158
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Fremont - Rideout Cancer Center
Marysville, California, 95901
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Kaiser Permanente Tysons Corner Medical Center
McLean, Virginia, 22102
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Aspirus Medford Hospital
Medford, Wisconsin, 54451
Riddle Memorial Hospital
Media, Pennsylvania, 19063
Summa Health Medina Medical Center
Medina, Ohio, 44256
Garnet Health Medical Center
Middletown, New York, 10940
Bayhealth Hospital Sussex Campus
Milford, Delaware, 19963
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53209
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Kaiser Permanente-Modesto
Modesto, California, 95356
Monticello Cancer Center
Monticello, Minnesota, 55362
Saint Joseph Mount Sterling
Mount Sterling, Kentucky, 40353
Marshfield Medical Center - Neillsville
Neillsville, Wisconsin, 54456
About this study
Official title: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Read the detailed description
PRIMARY OBJECTIVE:
- To compare persistence with the initially prescribed oral endocrine therapy (ET) through 72 weeks for young women being treated for hormone-receptor positive stage I-III breast cancer randomized to Active Symptom Monitoring (ASM) + patient education or patient education alone.
SECONDARY OBJECTIVES:
- To compare patient-reported adherence with the initially prescribed oral ET over time as assessed with the Voils measure between the two arms.
II. To compare worst pain as assessed with the Brief Pain Inventory, in aromatase inhibitors-treated (AI-treated) participants over time between the two arms.
III. To compare hot flashes as assessed with the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Endocrine Symptoms Scale in tamoxifen-treated participants over time between the two arms.
EXPLORATORY OBJECTIVES:
- To describe key treatment-emergent symptoms as assessed with the Brief Pain Inventory, the Patient-Reported Outcomes Measurement Information System (PROMIS-29) Profile, the PROMIS Cognitive Function, and the FACT-ES Endocrine Symptoms Scale over time between the two arms.
II. To develop a composite risk prediction model (including demographics, socioeconomic variables, and clinical variables) to identify participants who are most likely to benefit from ASM.
III. To examine associations between baseline symptom bother as assessed with the GP5 item from the FACT-ES and persistence with oral ET.
IV. To examine the pattern by arm of treatment toxicity from the oral ET agents that are prescribed in this study over time during the first 24 weeks.
- To compare biochemically determined adherence with the initially prescribed oral ET as assessed with centrally evaluated drug concentrations and metabolites between ASM + patient education and patient education alone over time.
VI. To examine associations overall and by arm between baseline estradiol concentrations evaluated centrally and development of treatment-emergent symptoms as assessed with the Brief Pain Inventory, the PROMIS-29 Profile, the PROMIS Cognitive Function, and the FACT-ES endocrine symptoms scale.
VII. To determine patterns of change overall and by arm in centrally evaluated estradiol concentrations during study participation in participants with chemotherapy-induced ovarian failure, those receiving gonadotrophin releasing hormone (GnRH) agonist therapy, and those who had undergone bilateral salpingo-oophorectomy.
VIII: To identify inherited genetic variants using genome-wide genotyping that contribute to development of endocrine therapy-emergent toxicity.
BANKING OBJECTIVE:
- To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months.
ARM II: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
- Being tested
- Best Practice, Biospecimen Collection, Endocrine Drug Therapy, Health Education, Questionnaire Administration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Best PracticeOther
Also called standard of care, standard therapy
Standard of care hormone therapy and standard visit with clinician
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo correlative studies
Endocrine Drug TherapyProcedure or surgery
Undergo endocrine therapy
Health EducationBehavioural
Receive list of websites
Questionnaire AdministrationOther
Ancillary studies
Symptom Specific Assessment ToolOther
Also called Symptom Assessment Tool, Symptom-Specific Assessment Tool
Receive a weblink via email or text message and asked 6 brief questions about symptoms
| Study group | Role | What they receive |
|---|---|---|
| ARM I (ET, health education, symptom assessment) | Experimental | Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months. Receives: Other: Best Practice; Procedure: Biospecimen Collection; Procedure: Endocrine Drug Therapy; Behavioral: Health Education; Other: Questionnaire Administration; Other: Symptom Specific Assessment Tool |
| ARM II (ET, health education) | Active comparator | Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months. Receives: Other: Best Practice; Procedure: Biospecimen Collection; Procedure: Endocrine Drug Therapy; Behavioral: Health Education; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Persistence with initially prescribed oral estrogen (ET) medication
Will be assessed by the treating provider at each study visit every 12 weeks and prospectively documented on the S2010 treatment log, including any switch from the initially prescribed oral ET. Persistence with initially prescribed oral ET by intervention arm out to 72 weeks will be described using Kaplan-Meier plots. Potential differences by arm will be tested using multivariable Cox regression. Persistence with any oral ET (aromatase inhibitor [AI] and/or tamoxifen) at 72 weeks by arm will be examined in a consistent manner. The study stratification variables (age [< 45 vs >= 45], chemotherapy [yes/no], and ET [AI vs tamoxifen]), as well as race, ethnicity, and disease stage, will be included as covariates in the regression models. In the timeframe of evaluation, censored events (newly diagnosed cancer, cancer recurrence, or death) are anticipated to be low.
Measured: From randomization to discontinuation of the initially prescribed ET for more than 60 days or switching to a new oral ET medication, assessed up to 72 weeks
Secondary outcomes (3)
Occurrence of any non-adherence
Will be assessed using the Voils validated adherence tool that both determines the extent of nonadherence as well as reasons for non-adherence. Kaplan Meier plots will be used to describe patterns of non-adherence between arms. Multivariable Cox regression will be used to assess this secondary endpoint.
Measured: Up to 18 months
Worst pain
Will be measured using the Brief Pain Inventory - Short Form (BPI-SF) "worst pain" question ("Please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours") in the subset of patients planning to receive AI treatment. Worst pain is measured on an 11-point scale of 0 ("no pain") to 10 ("pain as bad as you can imagine"). Linear regression will be used, adjusting for the stratification factors and the baseline score.
Measured: Up to 12 weeks
Incidence of hot flashes
Will be assessed using the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) "I have hot flashes/hot flushes" (ES1) question in the subset of patients planning to receive tamoxifen therapy. Hot flashes/hot flushes are measured on a scale of 0 ("not at all") to 4 ("very much"), with higher values indicating increased concern over the past 7 days. Linear regression will be used to compare scores between arms, adjusting for the stratification factors and the baseline score.
Measured: Up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2022
- Study start29 Mar 2023
- Primary completion1 May 2027 (estimated)
- Study completion1 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anatomic Stage I Breast Cancer AJCC v8Studies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 565 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Norah L Henry, Principal investigator, SWOG Cancer Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05568472
- Sponsor's protocol ID
- S2010
- Other IDs
- NCI-2022-06902, S2010, SWOG-S2010, S2010, R01CA266012, UG1CA189974
- Status last verified
- Apr 2026
- First submitted
- 23 Sep 2022
- Last updated
- 2 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Henry NL, Unger JM, Vaidya R, Darke AK, Skaar TC, Fisch MJ, Hershman DL. Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. Contemp Clin Trials. 2024 Dec;147:107712. doi: 10.1016/j.cct.2024.107712. Epub 2024 Oct 10.
PubMed 39395534
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
- ClinicalTrials.gov ID
- NCT05568472
- Acronym / sponsor ID
- S2010
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 565 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 29 Mar 2023 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 1 May 2028 (estimated)
- First posted
- 5 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Detailed description
PRIMARY OBJECTIVE:
- To compare persistence with the initially prescribed oral endocrine therapy (ET) through 72 weeks for young women being treated for hormone-receptor positive stage I-III breast cancer randomized to Active Symptom Monitoring (ASM) + patient education or patient education alone.
SECONDARY OBJECTIVES:
- To compare patient-reported adherence with the initially prescribed oral ET over time as assessed with the Voils measure between the two arms.
II. To compare worst pain as assessed with the Brief Pain Inventory, in aromatase inhibitors-treated (AI-treated) participants over time between the two arms.
III. To compare hot flashes as assessed with the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Endocrine Symptoms Scale in tamoxifen-treated participants over time between the two arms.
EXPLORATORY OBJECTIVES:
- To describe key treatment-emergent symptoms as assessed with the Brief Pain Inventory, the Patient-Reported Outcomes Measurement Information System (PROMIS-29) Profile, the PROMIS Cognitive Function, and the FACT-ES Endocrine Symptoms Scale over time between the two arms.
II. To develop a composite risk prediction model (including demographics, socioeconomic variables, and clinical variables) to identify participants who are most likely to benefit from ASM.
III. To examine associations between baseline symptom bother as assessed with the GP5 item from the FACT-ES and persistence with oral ET.
IV. To examine the pattern by arm of treatment toxicity from the oral ET agents that are prescribed in this study over time during the first 24 weeks.
- To compare biochemically determined adherence with the initially prescribed oral ET as assessed with centrally evaluated drug concentrations and metabolites between ASM + patient education and patient education alone over time.
VI. To examine associations overall and by arm between baseline estradiol concentrations evaluated centrally and development of treatment-emergent symptoms as assessed with the Brief Pain Inventory, the PROMIS-29 Profile, the PROMIS Cognitive Function, and the FACT-ES endocrine symptoms scale.
VII. To determine patterns of change overall and by arm in centrally evaluated estradiol concentrations during study participation in participants with chemotherapy-induced ovarian failure, those receiving gonadotrophin releasing hormone (GnRH) agonist therapy, and those who had undergone bilateral salpingo-oophorectomy.
VIII: To identify inherited genetic variants using genome-wide genotyping that contribute to development of endocrine therapy-emergent toxicity.
BANKING OBJECTIVE:
- To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months.
ARM II: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ARM I (ET, health education, symptom assessment) | Experimental | Other: Best Practice, Procedure: Biospecimen Collection, Procedure: Endocrine Drug Therapy, Behavioral: Health Education, Other: Questionnaire Administration, Other: Symptom Specific Assessment ToolPatients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months. |
| ARM II (ET, health education) | Active comparator | Other: Best Practice, Procedure: Biospecimen Collection, Procedure: Endocrine Drug Therapy, Behavioral: Health Education, Other: Questionnaire AdministrationPatients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Participants must be female and have Stage I, II, or III hormone receptor positive breast cancer based on clinical or pathologic evaluation
- Participants must have been pre- or peri-menopausal at the time of breast cancer diagnosis by satisfying one of the following:
- Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole; within 14 days prior to randomization or be planning to start initial treatment with standard of care oral ET within 14 days after randomization
- Participants who currently have ovarian function (estradiol above the postmenopausal range) must be planning to undergo ovarian suppression or ablation concomitantly with oral ET medication, starting before or at the same time as oral ET initiation. Participants with chemotherapy-induced amenorrhea or ovarian failure at time of registration must be planning to start ovarian suppression or ablation if they have recurrence of ovarian function during study participation (circulating estradiol concentration in the premenopausal range or recurrence of menses)
- Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization NOTE: Concomitant radiotherapy at the time of randomization and/or during study participation is allowed
Key exclusion criteria (10 listed)
- Participants must not have distant metastatic breast cancer
- Participants who have started or plan to start treatment with tamoxifen during study participation must not have received prior tamoxifen for treatment or prevention of breast cancer
- Participants who have started or plan to start treatment with an aromatase inhibitor during study participation must not have received prior aromatase inhibitor therapy for treatment or prevention of breast cancer
- Participants must not be taking or planning to take oral estrogen-or progesterone-containing treatments during study participation
- Participants who start or plan to start treatment with an aromatase inhibitor may have previously received tamoxifen for prevention of breast cancer or treatment of a prior cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Best PracticeAlso: standard of care, standard therapyStandard of care hormone therapy and standard visit with clinician | Other | ARM I (ET, health education, symptom assessment), ARM II (ET, health education) |
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Specimen CollectionUndergo correlative studies | Procedure or surgery | ARM I (ET, health education, symptom assessment), ARM II (ET, health education) |
| Endocrine Drug TherapyUndergo endocrine therapy | Procedure or surgery | ARM I (ET, health education, symptom assessment), ARM II (ET, health education) |
| Health EducationReceive list of websites | Behavioural | ARM I (ET, health education, symptom assessment), ARM II (ET, health education) |
| Questionnaire AdministrationAncillary studies | Other | ARM I (ET, health education, symptom assessment), ARM II (ET, health education) |
| Symptom Specific Assessment ToolAlso: Symptom Assessment Tool, Symptom-Specific Assessment ToolReceive a weblink via email or text message and asked 6 brief questions about symptoms | Other | ARM I (ET, health education, symptom assessment) |
Primary outcome
Persistence with initially prescribed oral estrogen (ET) medication
Time frame: From randomization to discontinuation of the initially prescribed ET for more than 60 days or switching to a new oral ET medication, assessed up to 72 weeks
Will be assessed by the treating provider at each study visit every 12 weeks and prospectively documented on the S2010 treatment log, including any switch from the initially prescribed oral ET. Persistence with initially prescribed oral ET by intervention arm out to 72 weeks will be described using Kaplan-Meier plots. Potential differences by arm will be tested using multivariable Cox regression. Persistence with any oral ET (aromatase inhibitor [AI] and/or tamoxifen) at 72 weeks by arm will be examined in a consistent manner. The study stratification variables (age [< 45 vs >= 45], chemotherapy [yes/no], and ET [AI vs tamoxifen]), as well as race, ethnicity, and disease stage, will be included as covariates in the regression models. In the timeframe of evaluation, censored events (newly diagnosed cancer, cancer recurrence, or death) are anticipated to be low.
3 secondary outcomes
Occurrence of any non-adherence
Time frame: Up to 18 months
Worst pain
Time frame: Up to 12 weeks
Incidence of hot flashes
Time frame: Up to 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2026.
- Derived from this study: PubMed 39395534Henry NL, Unger JM, Vaidya R, Darke AK, Skaar TC, Fisch MJ, Hershman DL. Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. Contemp Clin Trials. 2024 Dec;147:107712. doi: 10.1016/j.cct.2024.107712. Epub 2024 Oct 10.
Related trials for Anatomic Stage I Breast Cancer AJCC v8
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingPhase 2
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
RecruitingPhase 2
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Recruiting
Researching the Effect of Exercise on Cancer
Breast Cancer, Prostate Cancer
RecruitingPhase 1/2
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Norah L Henry principal investigator
SWOG Cancer Research Network
490 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Best Practice, Biospecimen Collection and Endocrine Drug Therapy in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, run by SWOG Cancer Research Network at 490 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 490 sites in United States, Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Persistence with initially prescribed oral estrogen (ET) medication (time frame: From randomization to discontinuation of the initially prescribed ET for more than 60 days or switching to a new oral ET medication, assessed up to 72 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05568472, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.